All In Biotech

Drug Trial Radar · NCT07755371

A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Rhinosinusitis With Nasal Polyps

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study Evaluating the Efficacy and Safety of AK139 in Participants With Chronic Rhinosinusitis With Nasal Polyps

Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Aug 10, 2026

Primary completion

Apr 30, 2027

Study completion Jul 31, 2027

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Aug 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AK139 injection compared with placebo in participants with chronic rhinosinusitis with nasal polyps (CRSwNP) receiving background treatment with mometasone furoate nasal spray (MFNS).

Conditions

  • Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Interventions

  • AK139Biological

    AK139 administered subcutaneously

  • PlaceboBiological

    Placebo administered subcutaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Nasal Polyp Score (NPS)Time frame: Baseline and Week 16
  2. Nasal Congestion Score (NCS)Time frame: Baseline and Week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Eye & ENT Hospital of Fudan University

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.